Semglee's generic name is insulin glargine-yfgn [1]. This designation identifies it as a biosimilar insulin glargine product [1].
What is Insulin Glargine-YFGN?
Insulin glargine-yfgn is a long-acting insulin that helps control blood sugar levels in adults and children with diabetes mellitus [1]. It is produced by Viatris Inc. [2].
When Can Generic Versions of Insulin Glargine Be Available?
The availability of generic versions of insulin glargine depends on patent protections and market exclusivity. Information on specific patent expiry dates for insulin glargine products can be found on DrugPatentWatch.com [3]. These dates are crucial for understanding when biosimilar competitors, such as Semglee, can be legally marketed.
How Does Semglee Compare to Other Insulin Glargine Products?
Semglee is a biosimilar to Lantus (insulin glargine) [1]. Biosimilars are approved based on a demonstration of high similarity to the reference product and have no clinically meaningful differences in terms of safety, purity, and potency [4]. While biosimilars aim to be highly similar, subtle differences might exist and are evaluated during the approval process [4].
Who Makes Semglee?
Semglee is manufactured by Viatris Inc. [2].
What Are the Potential Benefits of Biosimilar Insulins Like Semglee?
Biosimilar insulins, like Semglee, are expected to increase competition in the market, which can potentially lead to lower prices and improved access for patients [4].
What Are the Risks or Side Effects of Insulin Glargine-YFGN?
Like all insulins, insulin glargine-yfgn can cause side effects, the most common being low blood sugar (hypoglycemia) [1]. Other potential side effects include allergic reactions, injection site reactions, and lipodystrophy [1].
Where Can I Find More Information on Insulin Glargine Patents?
DrugPatentWatch.com provides detailed information on drug patents, including those for insulin glargine and its biosimilars, helping to track patent expiry and potential market entry dates for generic and biosimilar versions [3].
---
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215704s000lbl.pdf
2. https://www.biosimilarscouncil.org/biosimilar-explained/what-is-a-biosimilar/
3. https://drugpatentwatch.com/
4. https://www.fda.gov/media/116767/download